LMW Solutes
|
|
Phenylacetic acid (PAA) |
Macrophages: inducible nitric oxide synthase ↓ [106]; |
PMNLs: oxidative burst, phagocytosis and integrin expression ↑; apoptosis ↓ [49] |
Dinucleoside polyphosphates |
Leukocytes: oxidative burst ↑ [107]. |
Guanidino compounds |
Monocytes/macrophages: pro- and anti-inflammatory [108,109,110] |
Indoxyl sulfate |
Endothel: E-selectin ↑ [111] |
P-cresyl sulfate |
Leukocytes: basal oxidative burst ↑ [112] |
Homocysteine (Hcy) |
ICAM-1 ↑ [113]; damage of DNA [114] and proteins [115] |
Methylglyoxal (MGO) |
PMNLs: apoptosis ↑ [116], oxidative burst ↑ [117]; |
Monocytes: apoptosis ↑ [118] |
Middle Molecules, Proteins
|
|
Immunoglobulin light chains (IgLCs) |
PMNLs: chemotaxis ↓, glucose uptake stimulation ↓, glucose uptake basal ↑ [119]; apoptosis ↓ [47] |
Retinol binding protein (RBP) |
PMNLs: chemotaxis ↓, oxidative burst ↓, apoptosis ↓ [120] |
Leptin |
PMNLs: chemotaxis ↓, oxidative burst ↓ [121] |
Resistin |
PMNLs: chemotaxis ↓, oxidative burst ↓ [122] |
Tamm-Horsfall protein (THP) |
PMNLs: (high concentrations) apoptosis ↓, chemotaxis ↓, phagocytosis ↑; (low concentrations) chemotaxis ↑ [123] |
High-density lipoprotein (HDL) |
Loss of anti-inflammatory properties in uremia [124,125] |
Protein Modifications
|
|
Glucose-modified proteins |
PMNLs: chemotaxis ↑, glucose uptake ↑, apoptosis ↑ [48] |
AGE-modified albumin |
Leukocytes: activating, pro- atherogenic [126] |
AGEs |
Macrophages: TNF and IL-1 secretion ↑ [127] |
Monocytes: Chemotaxis ↑ [128] |
Glycated collagen |
PMNLs: Adhesion ↑ [129] |
Advanced oxidation protein products (AOPPs) |
PMNLs and monocytes: oxidative burst ↑ [130] |
Oxidized low-density lipoproteins (oxLDLs) |
Macrophage activation [131]; |
PMNLs and eosinophils: chemotaxis ↑, degranulation ↑ [132]; |
Regulatory T cells: proteasome activity ↓ → cell cycle arrest and apoptosis [133] |
Homocysteinylated albumin |
Monocytes: adhesion ↑[134] |